Principle Wealth Partners LLC Increases Holdings in Eli Lilly and Company (NYSE:LLY)

Principle Wealth Partners LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 10.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,422 shares of the company’s stock after purchasing an additional 620 shares during the period. Principle Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $3,744,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of LLY. International Assets Investment Management LLC boosted its holdings in shares of Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares during the period. Sapient Capital LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $617,312,000. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $435,736,000. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after purchasing an additional 659,838 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Eli Lilly and Company by 24.2% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock valued at $1,778,362,000 after purchasing an additional 645,473 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of a number of analyst reports. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Bank of America upped their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. The Goldman Sachs Group upped their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. BMO Capital Markets upped their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Finally, DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a report on Wednesday, February 21st. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded up $8.64 during mid-day trading on Friday, hitting $733.51. The stock had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The company has a 50 day moving average of $761.79 and a two-hundred day moving average of $666.67. Eli Lilly and Company has a twelve month low of $380.77 and a twelve month high of $800.78. The firm has a market cap of $696.95 billion, a PE ratio of 126.47, a PEG ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the prior year, the firm earned $2.09 EPS. The firm’s revenue was up 28.1% on a year-over-year basis. Research analysts predict that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.